Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$20.79 USD
-0.56 (-2.62%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.79 USD
-0.56 (-2.62%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
Catalyst Pharmaceutical (CPRX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $15.76, marking a -1.62% move from the previous day.
3 Reasons Growth Investors Will Love Catalyst (CPRX)
by Zacks Equity Research
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Catalyst Pharmaceutical (CPRX) closed at $16.52 in the latest trading session, marking a +0.24% move from the prior day.
Catalyst Pharmaceutical (CPRX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $17.82, moving -1.44% from the previous trading session.
Catalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Relay Therapeutics, Inc. (RLAY) Surges 13.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Catalyst Pharmaceutical (CPRX) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $17.55, making no change from the previous trading session.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics
by Zacks Equity Research
Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as the Drug Industry Rebounds in 2023
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.
Here's Why You Should Retain Molina (MOH) in Your Portfolio
by Zacks Equity Research
Molina's (MOH) inorganic growth activities, financial flexibility and cost-cutting initiatives poise it well for growth.
Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $16.78, marking a -0.94% move from the previous day.
Should JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPSE
Here is Why Growth Investors Should Buy Catalyst (CPRX) Now
by Zacks Equity Research
Catalyst (CPRX) possesses solid growth attributes, which could help it handily outperform the market.
Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock
by Zacks Equity Research
Catalyst (CPRX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Stevanato Group S.p.A. (STVN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Stevanato (STVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Teleflex (TFX) Urolift Market Expansion Strong, Cost Woe Stays
by Zacks Equity Research
Teleflex (TFX) plans to spend 2023 training surgeons, building its presence in key cities and continuing to engage with the Chinese Urological Society to build acceptance.
Thermo Fisher (TMO) Partners With ArsenalBio for Cancer R&D
by Zacks Equity Research
Thermo Fisher's (TMO) latest collaboration with ArsenalBio supports the latter's clinical manufacturing of autologous T-cell therapies for advanced cancer treatment.
Masimo (MASI) Unveils Freedom Smartwatch With Privacy Switch
by Zacks Equity Research
Masimo's (MASI) newest wearable product seamlessly integrates continuous health tracking technology and breakthrough features.
Insulet (PODD) Benefits From Omnipod 5 Launch, Expansion
by Zacks Equity Research
Insulet (PODD) witnesses continued uptake of Omnipod through the U.S. pharmacy channel.
CVS Health (CVS) Nears Completion of $8B SGFY Acquisition
by Zacks Equity Research
According to CVS Health (CVS), Signify Health, a leading healthcare platform, is set to play a critical role in advancing its healthcare services strategy.
Thermo Fisher (TMO) Opens New Cell Therapy Facility at UCSF
by Zacks Equity Research
Thermo Fisher's (TMO) new cell therapy facility at UCSF is likely to accelerate the development of advanced therapies.
Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $16.44, marking a +1.99% move from the previous day.
Encompass Health (EHC) Opens JV Hospital for Oklahoma Patients
by Zacks Equity Research
Encompass Health (EHC) inaugurated the Owasso-based Ascension St. John Rehabilitation Hospital, that it will operate jointly with Ascension St. John to offer rehabilitative care in Oklahoma.
Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales decline reflects lower demand for COVID-19 services.